A085660 Stock Overview
CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services.
Capture your thoughts, links and company narrative
CHA Biotech Co., Ltd. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩15,410.00|
|52 Week High||₩18,250.00|
|52 Week Low||₩11,930.00|
|1 Month Change||16.48%|
|3 Month Change||8.75%|
|1 Year Change||-14.15%|
|3 Year Change||-31.21%|
|5 Year Change||-18.03%|
|Change since IPO||106.47%|
Recent News & Updates
|A085660||KR Healthcare||KR Market|
Return vs Industry: A085660 underperformed the KR Healthcare industry which returned 16.9% over the past year.
Return vs Market: A085660 underperformed the KR Market which returned -2.5% over the past year.
|A085660 Average Weekly Movement||4.6%|
|Healthcare Industry Average Movement||6.2%|
|Market Average Movement||5.7%|
|10% most volatile stocks in KR Market||12.3%|
|10% least volatile stocks in KR Market||2.9%|
Stable Share Price: A085660 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: A085660's weekly volatility (5%) has been stable over the past year.
About the Company
|2002||266||Hoon Oh Sang||https://www.chabio.com|
CHA Biotech Co., Ltd., together with its subsidiaries, engages in cell therapy development, cord blood, and stem cell banking services. The company operates a cord blood consignment storage business for the treatment of intractable diseases, as well as provides regenerative medicines, Immune and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs comprising fitness, spa, and supplements; and customized development, production, clinical, and commercialization services to customers with research and development, and clinical experience. It also offers optimized IT system construction and operation; consulting services for development, operation, and expansion of Chaum model; and solutions for maternal-centered genome testing and personalized healthcare.
CHA Biotech Co., Ltd. Fundamentals Summary
|A085660 fundamental statistics|
Is A085660 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A085660 income statement (TTM)|
|Cost of Revenue||₩666.25b|
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
|Earnings per share (EPS)||-674.89|
|Net Profit Margin||-4.15%|
How did A085660 perform over the long term?See historical performance and comparison